EP3717093A1 - Extraction and purification of cannabinoid compounds - Google Patents
Extraction and purification of cannabinoid compoundsInfo
- Publication number
- EP3717093A1 EP3717093A1 EP18880135.1A EP18880135A EP3717093A1 EP 3717093 A1 EP3717093 A1 EP 3717093A1 EP 18880135 A EP18880135 A EP 18880135A EP 3717093 A1 EP3717093 A1 EP 3717093A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ethanol
- cbd
- water
- extracted
- polar solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 58
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 58
- 238000000605 extraction Methods 0.000 title claims description 29
- 150000001875 compounds Chemical class 0.000 title description 24
- 238000000746 purification Methods 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 361
- 239000002904 solvent Substances 0.000 claims abstract description 42
- 229940065144 cannabinoids Drugs 0.000 claims abstract description 30
- 239000002798 polar solvent Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000005406 washing Methods 0.000 claims abstract description 23
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 9
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 9
- 150000007524 organic acids Chemical class 0.000 claims abstract description 9
- 241000218236 Cannabis Species 0.000 claims abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 20
- 241000196324 Embryophyta Species 0.000 claims description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 239000003599 detergent Substances 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- JWJSHFMHZAMORW-UHFFFAOYSA-N N,N-dimethylmethanamine methanamine Chemical compound NC.CN(C)C JWJSHFMHZAMORW-UHFFFAOYSA-N 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 4
- 239000012535 impurity Substances 0.000 abstract description 3
- 239000004094 surface-active agent Substances 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000002585 base Substances 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 100
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 100
- 229950011318 cannabidiol Drugs 0.000 description 100
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 100
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 96
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 87
- 240000004308 marijuana Species 0.000 description 82
- 239000000523 sample Substances 0.000 description 68
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 55
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 55
- 235000009120 camo Nutrition 0.000 description 50
- 235000005607 chanvre indien Nutrition 0.000 description 50
- 239000011487 hemp Substances 0.000 description 50
- 239000011347 resin Substances 0.000 description 48
- 229920005989 resin Polymers 0.000 description 48
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 40
- 239000000284 extract Substances 0.000 description 40
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 38
- 229960004242 dronabinol Drugs 0.000 description 38
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 27
- 238000000926 separation method Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000001514 detection method Methods 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- -1 isoprenoid compounds Chemical class 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000011258 core-shell material Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 101100238610 Mus musculus Msh3 gene Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 150000007522 mineralic acids Chemical group 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000004810 partition chromatography Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229920006395 saturated elastomer Chemical class 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101500027797 Thermococcus kodakarensis (strain ATCC BAA-918 / JCM 12380 / KOD1) Homing endonuclease PI-PkoI Proteins 0.000 description 1
- 206010046823 Uterine spasm Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 1
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 1
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000001211 electron capture detection Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000000050 ionisation spectroscopy Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 238000010844 nanoflow liquid chromatography Methods 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0215—Solid material in other stationary receptacles
- B01D11/0219—Fixed bed of solid material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
Definitions
- the present invention relates to methods for the extraction of cannabinoid compounds from plant tissue.
- THC and CBD are non-polar isoprenoid compounds that are frequently found modified with carboxylic acid groups that renders them both polar and inactive (THCA and CBD A).
- THCA and CBDA can be decarboxylated by heat, causing the compounds to be both activated and rendered non-polar (lipophilic).
- the activation, i.e. decarboxylation, of CBDA or THCA results in the active ingredients CBD or THC.
- the activation of THC and CBD limits the solubility of THC and CBD in water, while rendering them soluble in organic solvents.
- activated cannabinoids may be extracted from plant tissue using organic solvents such as chloroform, acetonitrile, butane, hexane, isopropanol, butanol, methanol and others.
- organic solvents such as chloroform, acetonitrile, butane, hexane, isopropanol, butanol, methanol and others.
- these non-potable solvents may be harmful themselves or be contaminated with trace amounts of harmful solvents.
- the invention comprises a method of extracting a cannabinoid from a plant tissue, comprising the steps of:
- the plant tissue may be dried and/or ground before the heat activation step.
- the polar solvent comprises water, a water/alcohol mixture, an organic acid, or a salt solution, and may optionally include a surfactant.
- the selective solvent is one which selectively extracts cannabinoid compounds.
- the heated, activated plant tissue may be extracted with the selective solvent to produce an intermediate resin before washing with a polar solvent in step (b).
- the selective solvent comprises ethanol or ethyl acetate.
- cannabinoids conversion of non-active, carboxylated forms of cannabinoids into their non-polar active ingredients allows for the subsequent, preferential removal of components which are soluble in a polar solvent.
- the cannabinoids may then be extracted using a selective solvent, such as ethanol, which is preferred due to its potability.
- a selective solvent such as ethanol
- Non-polar activated cannabinoids such as THC and CBD are not soluble in polar solvents, therefore polar contaminants may be washed away using the polar solvent.
- the polar solvent may be modified with salts, buffers or inorganic or organic acids or bases.
- the non-polar cannabinoids may then be extracted in a potable selective solvent, such as ethanol, that contains no harmful residues.
- the extracted cannabinoids may be purified by chromatography and/or quantified by spectroscopic methods.
- cannabis plant tissue is heated using an oven or a water bath to cause the conversion of the native acid forms of the cannabinoids, such as
- the plant tissue is heated at a temperature between about 100° to about 140° C, for between about 30 minutes to about 2 hours, preferably at about l20°C for about 1 hour.
- the washing step uses a polar solvent comprising water, a water/alcohol mixture, water modified by salt, buffers, inorganic or organic acids or bases, potable organic solvents, and/or combinations thereof.
- the tissue or intermediate resin is washed in a polar solvent comprising a potable surfactant or emulsifying agent, such as deoxycholate or n-octylglucoside or other amphipathic detergents.
- the washing step is done at a refrigerated temperature, such as below about 5° C, more preferably below about 0° C, but obviously above the freezing temperature of the polar solvent.
- the heated and washed cannabis tissue is subsequently extracted with a potable organic solvent, such as >40% ethanol and preferably 80% ethanol (v:v).
- a potable organic solvent such as >40% ethanol and preferably 80% ethanol (v:v).
- the extraction step occurs at a refrigerated temperature, such as between about -80° C to about 5° C, and more preferably between about -20° C and about 0° C.
- the active cannabinoids extracted from washed tissue by the selective solvent may be subsequently purified or separated from other extracted components by chromatography, the separation may be performed by liquid
- chromatography optionally DEAE, CMC, QA, PS, normal phase, or reversed phase chromatography.
- the chromatography may be isocratic, step gradient or a linear gradient.
- the purity of the purified active ingredient may be quantified by liquid chromatography such as high-performance liquid chromatography (HPLC).
- HPLC high-performance liquid chromatography
- the HPLC is nanoflow liquid chromatography.
- the HPLC can be reverse phase HPLC, ion exchange HPLC or normal phase HPLC.
- the chromatography mobile phase can for example be isopropyl alcohol (IP A), methanol, ethanol, propanol, or acetonitrile.
- the stationary phase can for example be silica based or polymer based, for example silica particles modified with octadecyl carbon chain (Cl 8).
- the step of detecting one or more ionizable products using mass spectrometry comprises ionizing the one or more ionizable products, optionally by electrospray ionization (ESI) or Atmospheric Pressure Chemical Ionization (APCI) to produce one or more product ions with a selected signal -to-noise ratio, and subjecting the one or more product ions to MS, optionally tandem MS (MS/MS).
- the ionizing is positive ionization (e.g. using an acidic buffer in the mobile phase).
- the ionizing is negative ionization (e.g using a basic buffer in the mobile phase).
- the step of ionizing the one or more ionizable products comprises Matrix-assisted laser desorption/ionization (MALDI).
- Figure 1 is an illustration of a scheme to activate, wash, selectively extract, purify, identify and quantify the cannabinoid compounds.
- Spectra depicts (A) 3x blank (B) external CBD standard curve from 0-200uM (C) detection of CBD (m/z 315) in hemp A HA1 extract,
- Figure 4A - CBD alone; 4B - THC alone; 4C - CBD and THC separation on a 6 cm column; 4D, CBD and THC separation on a 15 cm column over KinetexTM coreshell resin.
- Gradients - Samples were diluted in B buffer (65% AcN, 5%FA) with gradient 0 min at 70%, 10 min linear gradient to 80%, held for 5 min at 80% and equilibrate at 70%(base peak).
- Figure 6A CBD and THC reference standard; 6B, CBD alone; 6C, THC alone; 6D, Sample A spiked with CBD-D3; 6E, Sample B spiked with THC-D3.
- FIG. 7 Decarboxylation of CBDa at different temperatures.
- CBD external standard curve B, Internal versus external CBD curve.
- C Illustration spectra of the detection of CBD (m/z 315) in a hemp sample heated to l20°C spiked with CBD-D3 (m/z 318) measured by isocratic separation over C18 resin.
- FIG. 9 EtOH gradient extraction of CBD.
- C CBD and CBDa extracted in an ethanol gradient from a hemp sample heated to l20°C for 1 hour.
- Sample 1 0.1% TFA in 80% EtOH pH>2 (not adjusted); Sample 2, 0.1% FA in 80% EtOH pH2 (not adjusted); Sample 3, 0.1% Acetic acid in 80% EtOH pH3 (not adjusted); Sample 4, lOmM Citric acid in 80% EtOH pH4; Sample 5, lOmM Citrate in 80% EtOH pH5; Sample 6, lOmM Citrate in 80% EtOH pH6; Sample 7, lOmM Tris in 80% EtOH pH7; Sample 8, lOmM Tricine in 80% EtOH pH8; Sample 9, 0.1%
- CBD yields from 5 sequential extractions with and without pre-washing with H20 (n 3).
- O.lg hemp was heated to l20°C for 1 hour and extracted in A, 5x H20;
- B 5x Acetonitrile
- C 5x Ethanol
- D 5x Acetonitrile pre-washed with 5x H20
- E 5x Ethanol pre-washed with 5x H20
- Figure 14A ⁇ 7.5 mg CBD was extracted from 0.5g hemp in 100 % Ethanol, diluted to 20% ethanol and loaded onto a ⁇ l00ul HiQ column. The column was washed with loading solvent prior to elution with increasing amounts of Ethanol (25, 30, 32.5, 35, 37.5, 40,
- Figure 16 The wash of intermediate resin from cannabis sample A.
- a 0.1 g aliquot of cannabis sample A was washed heated to l20°C for 1 hour, extracted in ethanol and dried under vacuum to make a intermediate resin.
- the water soluble components of the resin were washed in water or water modified with organic acid, ethanol, or salt.
- Figure 17 The wash of intermediate resin from cannabis sample B. A 0.1 g aliquot of cannabis sample A was washed heated to l20°C for 1 hour, extracted in ethanol and dried under vacuum to make an intermediate resin. The water soluble components of the resin were washed in water, water with 0.5% acetic acid (v:v), ethanol, or salt.
- Figure 18 The extraction of intermediate resin from cannabis sample A.
- a 0.1 g aliquot of cannabis sample A was washed heated to 120° C for 1 hour, extracted in ethanol and dried under vacuum to make a intermediate resin.
- the water soluble components of the resin were washed in water with 0.5% acetic acid (v:v) and extracted with 1 ml of the solvent shown.
- FIG. 19 The extraction of intermediate resin from cannabis sample B.
- a 0.1 g aliquot of cannabis sample B was washed heated to l20°C for 1 hour, extracted in ethanol and dried under vacuum to make a intermediate resin.
- the water soluble components of the resin were washed in water with 0.5% acetic acid (v:v) and extracted with 1 ml of the solvent shown.
- the present invention comprises methods of selectively extracting and purifying cannabinoids from plant tissue, such as cannabinoid plant tissue.
- Cannabinoids are compounds which act on or modulate cannabinoid receptors in cells, which can alter neurotransmitter release in the brain. Cannabinoids were originally found in Cannabis saliva I... the origin of marijuana and hashish. Marijuana or its components have been reported in the scientific literature to alleviate the symptoms of a broad range of conditions including multiple sclerosis and forms of muscular spasm, including uterine and bowel cramps; movement disorders; pain, including migraine headache; glaucoma, asthma, inflammation, insomnia, and high blood pressure. There may also be utility for cannabinoids as an oxytoxic, anxiolytic, anti-convulsive, anti-depressant and/or anti-psychotic agent, anti-cancer agent, or an appetite stimulant.
- cannabinoids Many chemically related compounds, collectively classified as cannabinoids, have been isolated from Cannabis plants.
- the cannabinoids usually divided in the groups of classical cannabinoids, non-classical cannabinoids, aminoalkylindole derivatives and eicosanoids.
- Classical cannabinoids such as THC or CBD are isolated from Cannabis sativa L., or they can comprise synthetic analogs of these compounds.
- Non-classical cannabinoids may comprise bi- or tricyclic analogs of tetrahydrocannabinol (THC), while aminoalkylindoles form a group which differs structurally substantially from classical and non-classical cannabinoids.
- THC tetrahydrocannabinol
- cannabinoids can include, but are not limited to, cannabinoid compounds that may naturally occur in different combinations and relative quantities in the plant tissues of various species, subspecies, hybrids, strains, chemovars, and other genetic variants of the genus Cannabis, including material that may variously be classified as“marijuana” and“hemp” in accordance with various legal or technical definitions and standards.
- An exemplary cannabinoid comprises THC, having the formula (I):
- CBD cannabidiol
- IUPAC 2-[(lR,6R)-6-isopropenyl-3-methylcyclohex-2-en-l-yl]-5-pentylbenzene- l,3-diol, having the formula (II):
- CBD is not known to have the psychotropic effects of THC, it is still considered to have a wide scope of potential therapeutic applications.
- CBD may be derived from industrial hemp which has negligible amounts of THC, and may be legally grown and consumed in Canada and the United States.
- Cannabinoid compounds may also include various other cannibinoids such as tetrahydrocannabinolic acid (THCA), delta-8-tetrahydrocannabinol (D8THC), cannabidiolic acid (CBD A), cannabinol (CBN), cannabinolic acid (CBNA),
- THCA tetrahydrocannabinolic acid
- D8THC delta-8-tetrahydrocannabinol
- CBD A cannabidiolic acid
- CBN cannabinol
- CBNA cannabinolic acid
- THCV tetrahydrocannabinovarin
- THCVA cannabidivarin
- CBDV cannabidivarin acid
- CBDA cannabigerol
- CBDA cannabigerolic acid
- CBC cannabichromene
- CBCA cannabichromenic acid
- CBND cannabinodiol
- CBNDA cannabinodiolic acid
- the term“selective” as used herein in reference to a solvent, a solid phase or chromatography system of a solvent or solid phase, is one that selectively extracts or purifies a target substance or compound, such as a cannabinoid, with greater specificity relative to another different substance or compound.
- the selective system purifies the target substance or compound by at least 2 fold, 3 fold, or 5 fold.
- Figure 1 is an illustration of a general scheme to activate, wash, selectively extract, purify, identify and quantify cannabinoid compounds from cannabis plant tissue.
- the invention may comprise a method of selectively extracting and purifying a cannabinoid from plant tissue comprising the steps of: a. preparing plant tissue in fresh or dried form;
- the cannabinoids from the extract can be purified by precipitation and/or partition chromatography drying.
- the cannabinoids can be detected by liquid chromatography electrospray or atmospheric pressure ionization and tandem mass spectrometry (MS/MS).
- the methods disclosed herein may be performed on finely divided plant tissue, such as fresh or dried tissue which has been cut, chopped, ground, mashed or otherwise processed to reduce particle size.
- the method may also be performed in solution in the absence of a solid phase, wherein the target substance is not in the solid phase but in a colloidal suspension or fine powder in water or otherwise suspended or emulsified in a liquid phase.
- the polar solvent comprises purified water, or water mixed with alcohol such as ethanol, preferably less than about 40% ethanol (v:v), or acetic acid, preferably less than about 5% acetic acid (v:v). It is preferred that all components are potable. As used herein, a potable component is one that is classified as“Generally Regarded as Safe” or“GRAS” by the United States FDA.
- Polar solvents have large dipole moments (“partial charges”); that is they contain bonds between atoms with very different electronegativities, such as oxygen and hydrogen.
- Non polar solvents contain bonds between atoms with similar electronegativities, such as carbon and hydrogen. Bonds between atoms with similar electronegativities will lack partial charges.
- the polar solvent is one with a dielectric constant greater than about 5.0 at 20° C, preferably greater than about 20, and more preferably greater than about 50.
- the washing polar solvent comprises a non-ionic, non polymeric detergent or a bile acid detergent, such as sodium deoxycholate.
- the wash solvent contains a potable buffer such as phosphate or carbonate buffer, such as Na 2 C03 or NaHCCri, an organic acid, such as acetic acid or formic acid, ammonia, ammonium hydroxide, methylamine trimethyl amine or the like.
- the polar solvent wash take place at a reduced temperature, preferably below about 5° C, and more preferably below about 0° C, but obviously above the freezing temperature of the solvent.
- a first wash in 0.5% acetic acid (v:v) may be repeated up to three times, followed by a second wash in 40% ethanol (v:v), repeated up to three times.
- v:v 0.5% acetic acid
- v:v 40% ethanol
- an initial wash in a weak organic acid may protonate water-soluble impurities, facilitating their dissolution in the aqueous phase.
- the subsequent washes in ethanol/water selectively removes additional polar impurities.
- the selective solvent is one which selectively extracts the activated
- the extract solvent comprises ethanol, or ethanol mixed in water, preferably greater than about 40% ethanol (v:v), more preferably 80% ethanol. Potable ethanol is intended for human consumption and contains no unacceptable residues of harmful solvents.
- the cannabinoid is selectively extracted with about 80% ethanol at a refrigerated temperature, preferably between about -80° C and about 5° C, and more preferably between about -20° C and 0° C.
- Extraction may be followed by precipitation or drying to recover the desired cannabinoid compounds.
- the extracted compounds may be purified by liquid partition chromatography as monitored by electrospray ionization or atmospheric pressure chemical ionization and tandem mass spectrometry (LC-ESI-MS/MS) is more sensitive and definitive than colorimetric, fluorescent, flame ionization, or electron capture detection and permits standards labelled with isotopes or isobaric tags. Since mass spectrometers can separate and analyze many analytes simultaneously using the methods described herein, it can allow identification and quantification of many different cannabinoids at the same time to levels far below that which is possible by direct mass spectrometric analysis.
- LC-ESI-MS/MS electrospray ionization or atmospheric pressure chemical ionization and tandem mass spectrometry
- hemp (mg).
- CBD (mg) (Mw x V(L) x M) x 1000. Standardize to 100.00 mg hemp:
- CBD yields from 5 sequential extractions with and without pre-washing with water (n 3). 0. lg hemp was heated to l20°C for 1 hour and extracted in:
- the mass yields and yield CBD of five fractions combined are shown in Table IIIA.
- the mass yields and yield CBD of the first three fractions combined are shown in Table IIIB.
- Samples were detected on a LC-ESI-MS using a 300 Angstrom 5 micron C18 porous resin. Mass is defined as the dry tissue product extracted.
- Table III The effect of multiple extracts of the yield and purity of CBD and THC from Cannabis tissue.
- 0.1 g of hemp was heated to 120° C and pre-washed 3x with PBS, PBS+600mM NaCl, 0.5% acetic acid (Hac), 0.5% ammonia or H 2 0, followed by 3 washes of 40% Ethanol.
- CBD was then extracted with 3x 500ul of 80% Ethanol and the three fractions were pooled.
- the samples pre-washed in EEO were extracted lx with lml of Ethanol.
- Pre-wash (mg) from from 0.100 from total in mass
- Figure 3 shows the separation and detection of CBD in hemp sample A on a 300 Angstrom 5 micron C18 porous resin by LC-ESI-MS with a isocratic HPLC in 70% AcN 0.1% formic acid.
- HA1 is a sample heated and extracted in 100% acetonitrile (AcN);
- HE8 is a sample heated and extracted in 80% EtOH; and
- Spectra depicts (A) 3x blank (B) external CBD standard curve from 0-200uM (C) detection of CBD (m/z 315) in hemp A HA1 extract, (D) HE8 extract (E) HE1 extract, (F) mix of HE8 and HE1 extract, (Cl) HA1 extract spiked with CBD-D3 (m/z 318), (Dl) HE8 extract spiked with CBD-D3, (El) HE1 extract spiked with CBD-D3 and (Fl) mix of HE8 and HE1 extract spiked with CBD-D3.
- Figure 5A shows the results for Sample 1 spiked with CBD-D3; and
- Figure 5B shows the results for Sample 2 spiked with CBD- D3;
- Figures 5C and 5D show CBD and THC reference standards respectively.
- Gradients - Samples were diluted in B buffer (65% AcN, 5%FA) with gradient 0 min at 70%, 10 min linear gradient to 80%, held for 5 min at 80% and equilibrate at 70% (base peak).
- Figure 6A shows the CBD and THC reference standard; 6B shows CBD alone; 6C shows THC alone; 6D shows sample A spiked with CBD-D3; 6E shows sample B spiked with THC-D3.
- Figure 7 shows the decarboxylation of CBDa at different temperatures.
- Figure 8A shows a CBD external standard curve.
- Figure 8B shows an internal versus external CBD curve.
- Figure 8C shows an illustration spectra of the detection of CBD (m/z 315) in a hemp sample heated to l20°C spiked with CBD-D3 (m/z 318) measured by isocratic separation over C18 resin.
- Figure 9 shows an EtOH gradient extraction of CBD.
- Figure 9A shows CBD extracted in ethanol gradient from a hemp sample heated to l20°C vs no heating control (0C);
- Figure 9B shows CBD and CBDa extracted in an ethanol gradient (from 0% to 100% vol in water) from the no heating control sample (0C);
- Figure 9C shows CBD and CBDa extracted in an ethanol gradient from a hemp sample heated to l20°C for 1 hour.
- Sample 1 0.1% TFA in 80% EtOH pH>2 (not adjusted); Sample 2, 0.1% FA in 80% EtOH pH2 (not adjusted); Sample 3, 0.1% Acetic acid in 80% EtOH pH3 (not adjusted); Sample 4, lOmM Citric acid in 80% EtOH pH4; Sample 5, lOmM Citrate in 80% EtOH pH5; Sample 6, lOmM Citrate in 80% EtOH pH6; Sample 7, lOmM Tris in 80% EtOH pH7; Sample 8, lOmM Tricine in 80% EtOH pH8; Sample 9, 0.1% Ethanolamine in 80% EtOH pH9; Sample 10, 0.1% Ethanolamine in 80% EtOH pHlO; Sample 11, 0.1% Ammonia in 80% EtOH rH ⁇ 10 (not adjusted); Sample 12, 80% EtOH in H20 (pH not adjusted).
- 0.1 g of hemp was heated to l20°C and extracted 3x in 100% ethanol. Extracts of 0.5 g total hemp per replicate were pooled and diluted with H 2 0 to the appropriate ethanol concentrations. Samples were loaded at 100% ethanol and decreasing to 10% ethanol onto the various resins (DEAE - Figure 13 A, CMS - Figure 13B, HiQ - Figure 13C, HiS - Figure 13D.
- the Flow Throughs (FT) were collected and analyzed by LC-ESI-MS.
- Figure 14A ⁇ 7.5 mg CBD was extracted from 0.5g hemp in 100 % Ethanol, diluted to 20% ethanol and loaded onto a ⁇ l00ul HiQ column. The column was washed with loading solvent prior to elution with increasing amounts of Ethanol (25, 30, 32.5, 35, 37.5, 40,
- Figure 16 shows the effect of a wash of intermediate resin from cannabis sample A.
- a 0.1 g aliquot of cannabis sample A was washed in water and heated to l20°C for 1 hour, extracted in ethanol and dried under vacuum to make an intermediate resin.
- the water soluble components of the resin were washed in water or water modified with 0.5% acetic acid (v:v), 40% ethanol, salt/ethanol and saturated salt.
- Figure 17 shows the results of a wash of intermediate resin from cannabis sample B.
- a 0.1 g aliquot of cannabis sample A was washed in water and heated to l20°C for 1 hour, extracted in ethanol and dried under vacuum to make an intermediate resin.
- the water soluble components of the resin were washed in water or water modified with 0.5% acetic acid, 40% ethanol, salt/ethanol and saturated salt. The results show that that 40% ethanol was a better polar solvent in removing soluble compounds compared to the other solvents from the resin in sample B.
- Figure 18 shows the results of a selective extraction of intermediate resin from cannabis sample A.
- a 0.1 g aliquot of cannabis sample B was washed in water and heated to 120° C for 1 hour, extracted in ethanol and dried under vacuum to make an intermediate resin.
- the water soluble components of the resin were washed in water modified with
- FIG. 19 shows the results of extraction of intermediate resin from cannabis sample B.
- a 0.1 g aliquot of cannabis sample B was washed in water and heated to l20°C for 1 hour, extracted in ethanol and dried under vacuum to make a intermediate resin.
- the water soluble components of the resin were washed in water modified with 0.5% acetic acid and extracted with 1 ml of a solvent: acetone, acetonitrile, ether, ethyl acetate, ethanol, hexane, isopropyl alcohol, and methanol.
- references in the specification to "one embodiment”, “an embodiment”, etc., indicate that the embodiment described may include a particular aspect, feature, structure, or characteristic, but not every embodiment necessarily includes that aspect, feature, structure, or characteristic. Moreover, such phrases may, but do not necessarily, refer to the same embodiment referred to in other portions of the specification. Further, when a particular aspect, feature, structure, or characteristic is described in connection with an embodiment, it is within the knowledge of one skilled in the art to combine, affect or connect such aspect, feature, structure, or characteristic with other embodiments, whether or not such connection or combination is explicitly described. In other words, any element or feature may be combined with any other element or feature in different embodiments, unless there is an obvious or inherent incompatibility between the two, or it is specifically excluded.
- ranges recited herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof, as well as the individual values making up the range, particularly integer values.
- a recited range e.g., weight percents or carbon groups
- Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, or tenths.
- each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762591053P | 2017-11-27 | 2017-11-27 | |
PCT/CA2018/051508 WO2019100172A1 (en) | 2017-11-27 | 2018-11-27 | Extraction and purification of cannabinoid compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3717093A1 true EP3717093A1 (en) | 2020-10-07 |
EP3717093A4 EP3717093A4 (en) | 2021-09-15 |
Family
ID=72291215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18880135.1A Withdrawn EP3717093A4 (en) | 2017-11-27 | 2018-11-27 | Extraction and purification of cannabinoid compounds |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP3717093A4 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3291807B1 (en) * | 2015-05-07 | 2019-09-25 | Mark Andrew Scialdone | Hydrogenation of cannabis oil |
-
2018
- 2018-11-27 EP EP18880135.1A patent/EP3717093A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3717093A4 (en) | 2021-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11498018B2 (en) | Extraction and purification of cannabinoid compounds | |
Liu et al. | Cannabis sativa bioactive compounds and their extraction, separation, purification, and identification technologies: An updated review | |
Cheigh et al. | Enhanced extraction of flavanones hesperidin and narirutin from Citrus unshiu peel using subcritical water | |
Wu et al. | Simultaneous determination of phenolic compounds in sesame oil using LC–MS/MS combined with magnetic carboxylated multi-walled carbon nanotubes | |
Sapozhnikova | Development of liquid chromatography–tandem mass spectrometry method for analysis of polyphenolic compounds in liquid samples of grape juice, green tea and coffee | |
CN102448925B (en) | Composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid and their derivatives and method of preparation thereof | |
CN109884207B (en) | A method for rapid and accurate analysis of polyphenol content in rapeseed oil | |
CA2660464A1 (en) | Processes for production of hoodia plant extracts containing steroidal glycosides | |
Xue et al. | Isolation and purification of anthocyanin from blueberry using macroporous resin combined Sephadex LH-20 techniques | |
CN102924416B (en) | Method for separating and purifying monomeric compounds from ash bark | |
Al-Khazrajy et al. | Determination of pharmaceuticals in freshwater sediments using ultrasonic-assisted extraction with SPE clean-up and HPLC-DAD or LC-ESI-MS/MS detection | |
Shaheen et al. | Isolation of four phenolic compounds from Mangifera indica L. flowers by using normal phase combined with elution extrusion two-step high speed countercurrent chromatography | |
Cai et al. | A simple sample preparation approach based on hydrophilic solid-phase extraction coupled with liquid chromatography–tandem mass spectrometry for determination of endogenous cytokinins | |
Çelik et al. | Multistage recovery process of phenolic antioxidants with a focus on hydroxytyrosol from olive mill wastewater concentrates | |
CN105601606B (en) | A kind of method for preparing high-purity nutgall catechin gallic acid ester GCG | |
Faccin et al. | Determination of phenolic compounds in extracts of Amazonian medicinal plants by liquid chromatography-electrospray tandem mass spectrometry | |
EP3717093A1 (en) | Extraction and purification of cannabinoid compounds | |
KR100558382B1 (en) | Method for preparing ginkgo biloba extract using supercritical fluid extraction | |
Crişan et al. | LC/MS analysis of aucubin and catalpol of some Veronica species | |
Latiff et al. | Liquid chromatography tandem mass spectrometry for the detection and validation of quercetin-3-O-rutinoside and myricetin from fractionated Labisia pumila var. alata | |
CA3159642A1 (en) | Devices, systems, and methods for heat activation and two-stage differential extraction of cannabinoids using potable ethanol and water | |
CN105693679B (en) | A kind of method for preparing high-purity nutgall catechin GC | |
CN104327026A (en) | Method of extracting and separating costunolide and dehydrocostuslactone | |
CN101348489A (en) | Valerian extract iridoidate compound | |
CN111820449B (en) | Method for extracting volatile oil from industrial hemp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200629 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210812 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01D 15/36 20060101ALN20210806BHEP Ipc: B01D 15/32 20060101ALN20210806BHEP Ipc: C07D 311/80 20060101ALI20210806BHEP Ipc: B01D 11/02 20060101AFI20210806BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20240209 |